Spain

financials earnings profit profit miss earnings miss decline revenue decline
Manufacturing

Rovi warns analyst profit consensus is 10% to 15% too high

Spanish CDMO Rovi is part of a parade of biopharma contractors struggling to keep their manufacturing businesses growing in a post-COVID world.
Fraiser Kansteiner Feb 13, 2025 9:58am
turning down money rejecting money business offer

Grifols deflects private equity firm's potential takeover offer

Nov 20, 2024 10:13am
deal handshake business cooperation partnerships

Teva inks cancer biosimilar marketing pact with mAbxience

Apr 4, 2024 10:33am
Drug inspection FDA regulatory submission

EMA halts manufacturing after inspection of Serra Pamies plant

Aug 22, 2023 1:54pm
concept of job dismissal with puzzle pieces

Grifols is the latest drugmaker to succumb to the layoff trend

Feb 15, 2023 5:56pm
Drug inspection FDA regulatory submission

FDA hits Spanish drug substance maker Bioiberica with a Form 483

Jun 16, 2022 10:50am